Skip to main content
. 2023 Jan 9;3(1):vbac100. doi: 10.1093/bioadv/vbac100

Fig. 5.

Fig. 5.

Prognosis prediction with decreased unlabeled data. SCAN’s performance dropped with less unlabeled data, which was more prominent for breast cancer